NCT02594267View on ClinicalTrials.gov

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

April 7, 2017

Study Completion Date

October 8, 2020

Conditions
Peripheral T-Cell Lymphoma (PTCL)
Interventions
DRUG

Pralatrexate Injection

"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone"

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

55905

Mayo Clinic, Rochester

77030

MD Anderson, Houston

98109

Seattle Cancer Care Alliance/University of Washington, Seattle

Sponsors

Collaborators (1)

Axis Clinicals Limited
All Listed Sponsors
collaborator

Axis Clinicals Limited

INDUSTRY

lead

Acrotech Biopharma Inc.

INDUSTRY

NCT02594267 - A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | Biotech Hunter | Biotech Hunter